Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer

Published:2019-10-18 Issue:12 Volume:20 Page:1072-1072
ISSN:1389-2010
Container-title:Current Pharmaceutical Biotechnology
language:en
Short-container-title:CPB

Author:

Zalazar Florencia¹,Luca Paola De¹,Gardner Kevin²,Figg William D.³,Meiss Roberto⁴,Spallanzani Raúl G.⁵,Vallecorsa Pablo⁶,Elguero Belén⁷,Cotignola Javier⁷,Vazquez Elba⁷,Siervi Adriana De¹

Affiliation:

1. Laboratorio de Oncologia Molecular y Nuevos Blancos Terapeuticos, Instituto de Biologia y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina

2. Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, United States

3. Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States

4. Departamento de Patología, Academia Nacional de Medicina, Buenos Aires, Argentina

5. Laboratorio de Fisiopatologia de la Inmunidad Innata, Instituto de Biologia y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET), Argentina

6. Departamento de Patologia, Academia Nacional de Medicina, Buenos Aires, Argentina

7. Laboratorio de inflamacion y cáncer, Departamento de Quimica Biologica, Facultad de Ciencias Exactas y Naturales (FCEN), Universidad de Buenos Aires (UBA), IQUIBICEN - CONICET, Buenos Aires, Argentina

Abstract

: Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: “Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. : Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. As such this article represents a severe abuse of the scientific publishing system. Bentham Science Publishers takes a very strong view on this matter and apologizes to the readers of the journal for any inconvenience this may cause.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science,Biotechnology